Programmed cell death protein 1/programmed death ligand-1 checkpoint blockade meets patient-derived organoids.
作者信息
Sun Lejia, Yang Huayu, Mao Yilei
机构信息
Department of Liver Surgery, Peking Union Medical College (PUMC) Hospital, PUMC & Chinese Academy of Medical Sciences, Beijing 100730, China.
出版信息
Ann Transl Med. 2019 Dec;7(Suppl 8):S287. doi: 10.21037/atm.2019.11.76.
Abstract
摘要
相似文献
1
Programmed cell death protein 1/programmed death ligand-1 checkpoint blockade meets patient-derived organoids.程序性细胞死亡蛋白1/程序性死亡配体1检查点阻断与患者来源的类器官相结合。
Ann Transl Med. 2019 Dec;7(Suppl 8):S287. doi: 10.21037/atm.2019.11.76.
2
Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy.调控肠道菌群：增强 PD-1 和 PD-L1 阻断治疗疗效的新策略。
Front Immunol. 2018 Mar 5;9:374. doi: 10.3389/fimmu.2018.00374. eCollection 2018.
3
Programmed death-1 checkpoint blockade in acute myeloid leukemia.急性髓系白血病中的程序性死亡-1检查点阻断
Expert Opin Biol Ther. 2015;15(8):1191-203. doi: 10.1517/14712598.2015.1051028. Epub 2015 Jun 3.
4
Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells.免疫细胞和肿瘤细胞程序性死亡配体1（B7-H1）的功能表达
Front Immunol. 2017 Aug 10;8:961. doi: 10.3389/fimmu.2017.00961. eCollection 2017.
5
Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8 lymphocytes in primary sarcomas is subtype dependent.程序性细胞死亡蛋白1、程序性死亡配体1和CD8淋巴细胞在原发性肉瘤中的表达及临床相关性取决于亚型。
Oncotarget. 2017 Jul 7;8(41):71371-71384. doi: 10.18632/oncotarget.19071. eCollection 2017 Sep 19.
6
Programmed death-1 immune checkpoint blockade in the treatment of hematological malignancies.程序性死亡-1免疫检查点阻断在血液系统恶性肿瘤治疗中的应用
Ann Med. 2016 Sep;48(6):428-439. doi: 10.1080/07853890.2016.1186827. Epub 2016 May 25.
7
Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancer.拮抗程序性死亡蛋白-1和程序性死亡配体-1作为胃癌的一种治疗方法。
Therap Adv Gastroenterol. 2016 Nov;9(6):853-860. doi: 10.1177/1756283X16658251. Epub 2016 Jul 21.
8
PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.PD-1/PD-L1 阻断疗法在晚期非小细胞肺癌中的应用：现状与未来方向。
Oncologist. 2019 Feb;24(Suppl 1):S31-S41. doi: 10.1634/theoncologist.2019-IO-S1-s05.
9
Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer.晚期微卫星不稳定胆道癌患者成功进行免疫检查点阻断治疗。
Cold Spring Harb Mol Case Stud. 2017 Sep 1;3(5). doi: 10.1101/mcs.a001974. Print 2017 Sep.
10
Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?对PD-L1/PD-1阻断免疫疗法的耐药性：一种肿瘤内在还是肿瘤外在现象？
Front Pharmacol. 2020 Apr 7;11:441. doi: 10.3389/fphar.2020.00441. eCollection 2020.
引用本文的文献
1
Organoid models of glioblastoma: advances, applications and challenges.胶质母细胞瘤的类器官模型：进展、应用与挑战
Am J Cancer Res. 2020 Aug 1;10(8):2242-2257. eCollection 2020.
本文引用的文献
1
One checkpoint may hide another: inhibiting the TGFβ signaling pathway enhances immune checkpoint blockade.一个检查点可能隐藏着另一个：抑制转化生长因子β信号通路可增强免疫检查点阻断作用。
Hepatobiliary Surg Nutr. 2019 Jun;8(3):289-294. doi: 10.21037/hbsn.2019.01.10.
2
Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy.错配修复缺陷/微卫星不稳定高作为抗 PD-1/PD-L1 免疫治疗疗效的预测指标。
J Hematol Oncol. 2019 May 31;12(1):54. doi: 10.1186/s13045-019-0738-1.
3
The new era of precision medicine in hepatocellular carcinoma: the urgent need for promising biomarkers.肝细胞癌精准医学的新时代：对有前景生物标志物的迫切需求。
Hepatobiliary Surg Nutr. 2018 Dec;7(6):490-491. doi: 10.21037/hbsn.2018.08.06.
4
Study progression of anti-angiogenetic therapy and its combination with other agents for the treatment of advanced hepatocellular carcinoma.抗血管生成疗法及其与其他药物联合治疗晚期肝细胞癌的研究进展。
Hepatobiliary Surg Nutr. 2018 Dec;7(6):466-474. doi: 10.21037/hbsn.2018.11.04.
5
Modelling cancer in microfluidic human organs-on-chips.在微流控人体器官芯片中模拟癌症。
Nat Rev Cancer. 2019 Feb;19(2):65-81. doi: 10.1038/s41568-018-0104-6.
6
Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade.分析前列腺癌中微卫星不稳定性的流行情况及对免疫检查点阻断的反应。
JAMA Oncol. 2019 Apr 1;5(4):471-478. doi: 10.1001/jamaoncol.2018.5801.
7
Organoid Modeling of the Tumor Immune Microenvironment.类器官肿瘤免疫微环境模型构建
Cell. 2018 Dec 13;175(7):1972-1988.e16. doi: 10.1016/j.cell.2018.11.021.
8
Patient-derived organoids: a promising model for personalized cancer treatment.患者来源的类器官：个性化癌症治疗的一个有前景的模型。
Gastroenterol Rep (Oxf). 2018 Nov;6(4):243-245. doi: 10.1093/gastro/goy040. Epub 2018 Oct 9.
9
Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of PD-1/PD-L1 checkpoint blockade.组氨酸靶向髓系来源的抑制细胞，提高 PD-1/PD-L1 检查点阻断的抗肿瘤疗效。
Cancer Immunol Immunother. 2019 Feb;68(2):163-174. doi: 10.1007/s00262-018-2253-6. Epub 2018 Oct 12.
10
Organoids in cancer research.类器官在癌症研究中的应用。
Nat Rev Cancer. 2018 Jul;18(7):407-418. doi: 10.1038/s41568-018-0007-6.
Zotero 插件